Glioma classification is moving from histopathology to genomics, transcriptomics and epigenomics classifiers5–8, with isocitrate dehydrogenase (IDH1/2) mutations and a chromosome 1p and 19q codeletion, among others, now commonly used for diagnosis and prognosis7. This evidence concerns the gene IDH1 and central nervous system cancer.